Pasireotide

Fat LossFDA-approved multi-receptor somatostatin analogEstablished

Pasireotide is an FDA-approved multi-receptor somatostatin analog. Pasireotide binds somatostatin receptor subtypes 1, 2, 3 and 5, with markedly higher affinity for subtype 5 than octreotide or lanreotide. Corticotroph adenomas in Cushing disease express subtype 5 predominantly, which is why pasireotide can suppress ACTH where subtype-2-selective analogs do not.

Calculate Dose

For research use only.

Key Facts

CAS: —
Molecular Weight (MW): 1047.2 g/mol
Half-life: —
FDA status: Approved
Evidence level: FDA Approved
Human dose established: Yes
Administration Route: Subcutaneous · Intramuscular
Frequency: Twice daily (Signifor); every 4 weeks (Signifor LAR)
Last updated: Nov 7, 2026
Reviewed: Nov 7, 2026

Research summary

Somatostatin analog with a broader receptor binding profile than octreotide, approved for Cushing disease and for acromegaly in patients inadequately controlled by surgery or other somatostatin analogs.

Research evidence

Regulatory review (FDA label)3 reviewed sources
Controlled human trialsNone in reviewed sources
Early or uncontrolled human studiesNone in reviewed sources
Lab & animal studiesNone in reviewed sources

How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Pasireotide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Pasireotide dosage evidence

Pasireotide has FDA-approved human dosages. Signifor for adults with Cushing's disease is 0.3–0.9 mg under the skin twice a day, starting at 0.6 or 0.9 mg. Signifor LAR is injected into the buttock muscle every 4 weeks: 10 mg to start in Cushing's disease (up to 40 mg) and 40 mg to start in acromegaly (up to 60 mg).

FDA Approved

Dosage evidence summary for Pasireotide
Human dosing established	Yes
Route	Subcutaneous · Intramuscular
Frequency	Twice daily (Signifor); every 4 weeks (Signifor LAR)
Duration studied	Long-term while benefit continues
Titration	Signifor: adjusted to urinary free cortisol and tolerability. Signifor LAR: in acromegaly up to 60 mg after 3 months at 40 mg; in Cushing's disease up from 10 mg after 4 months, to 40 mg at most; lowered in 20 mg steps (acromegaly) for side effects.
Evidence level	FDA Approved
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Pasireotide, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
FDA label — Signifor, Cushing's diseaseFDA-approved label · FDA prescribing information	Adults with Cushing's disease for whom pituitary surgery is not an option or was not curative	Start 0.6 mg or 0.9 mg; range 0.3–0.9 mg. Child-Pugh B: start 0.3 mg, maximum 0.6 mg	Subcutaneous	Twice daily	As long as benefit is derived	Lower 24-hour urinary free cortisol	SIGNIFOR (pasireotide) injection — FDA prescribing information, DailyMed
FDA label — Signifor LAR, acromegalyFDA-approved label · FDA prescribing information	Patients with acromegaly with an inadequate response to surgery or for whom surgery is not an option	Start 40 mg; up to 60 mg after 3 months if GH or IGF-1 are not normal. Child-Pugh B: start 20 mg, maximum 40 mg	Intramuscular, gluteal, by a healthcare professional	Every 4 weeks (28 days)	Long-term	GH and IGF-1 control	SIGNIFOR LAR (pasireotide) for injectable suspension — FDA prescribing information, DailyMed
FDA label — Signifor LAR, Cushing's diseaseFDA-approved label · FDA prescribing information	Patients with Cushing's disease for whom pituitary surgery is not an option or was not curative	Start 10 mg; after 4 months may be increased up to 40 mg. Child-Pugh B: start 10 mg, maximum 20 mg	Intramuscular, gluteal, by a healthcare professional	Every 4 weeks (28 days)	Long-term	Lower 24-hour urinary free cortisol	SIGNIFOR LAR (pasireotide) for injectable suspension — FDA prescribing information, DailyMed

Where sources disagree

Signifor (twice-daily injection) and Signifor LAR (monthly depot) use different doses and routes and are not interchangeable.
Both labels call for fasting glucose, HbA1c, liver tests, an ECG and potassium and magnesium levels before starting (Signifor also lists a gallbladder ultrasound), because pasireotide can raise blood sugar. Both say to avoid use in severe hepatic impairment (Child-Pugh C).

Pasireotide dosage in published studies and labels →

Sequence & molecular data

Sequence and molecular data for Pasireotide
Molecular formula	C58H66N10O9
Molecular weight	1047.2 g/mol
PubChem CID	9941444
FDA UNII	98H1T17066
ChEMBL	CHEMBL3349607
DrugBank	DB06663

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Pasireotide binds somatostatin receptor subtypes 1, 2, 3 and 5, with markedly higher affinity for subtype 5 than octreotide or lanreotide. Corticotroph adenomas in Cushing disease express subtype 5 predominantly, which is why pasireotide can suppress ACTH where subtype-2-selective analogs do not. The same broad receptor engagement contributes to a higher incidence of hyperglycaemia, driven by reduced insulin and incretin secretion.

Studies

Research statistics

692 PubMed publications · 40.3% human clinical research · 84 registered trials

Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted

Regulatory & research status

Pasireotide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

Regulatory and research status for Pasireotide
FDA status	Approved
Research status	Approved product (see FDA status)
Availability	Prescription-Only
WADA (sport)	Unknown / Not Listed
Library classification	FDA-Approved

How FDA approval, compounding and research-only status differ

Benefits

—

Pasireotide side effects

No side effects listed yet for this entry.

Storage & stability

This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.

Pasireotide: frequently asked questions

What is Pasireotide?

How does Pasireotide work?

Is Pasireotide FDA approved?

Yes. Pasireotide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

What peptides are similar to Pasireotide?

Compounds most often compared with Pasireotide include Octreotide, Lanreotide, Human Growth Hormone (Somatropin) and Lonapegsomatropin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Pasireotide-a novel somatostatin receptor ligand after 20 years of use — Rev Endocr Metab Disord, 2022
External reference
Pasireotide in Acromegaly: A Review — Drugs, 2015
External reference
Pasireotide, 2012
External reference
Pasireotide, 2006
External reference
Pasireotide as first line medical therapy for selected patients with acromegaly — Pituitary, 2025
External reference

Related research, comparisons & guides

Related peptides

Human Growth Hormone (Somatropin)

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2

This Pasireotide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Pasireotide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →